Markers or Makers
2019; Lippincott Williams & Wilkins; Volume: 73; Issue: 4 Linguagem: Norueguês
10.1161/hypertensionaha.119.12604
ISSN1524-4563
AutoresNatália R. Barbaro, David G. Harrison,
Tópico(s)Hormonal Regulation and Hypertension
ResumoHomeHypertensionVol. 73, No. 4Markers or Makers Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBMarkers or MakersInflammatory Cytokines in Treatment-Resistant Hypertension Natalia R. Barbaro and David G. Harrison Natalia R. BarbaroNatalia R. Barbaro From the Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN. and David G. HarrisonDavid G. Harrison Correspondence to David G. Harrison, Betty and Jack Bailey Professor of Medicine, Pharmacology and Physiology, Director of Clinical Pharmacology, Room 536, Robinson Research Bldg, Vanderbilt University, Nashville, TN 37232. Email E-mail Address: [email protected] From the Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN. Originally published19 Feb 2019https://doi.org/10.1161/HYPERTENSIONAHA.119.12604Hypertension. 2019;73:767–769This article is a commentary on the followingInflammation and Apparent Treatment-Resistant Hypertension in Patients With Chronic Kidney DiseaseOther version(s) of this articleYou are viewing the most recent version of this article. Previous versions: February 19, 2019: Ahead of Print See related article, pp 785–793Between 7% and 20% of the hypertensive population exhibits resistance to treatment, defined as blood pressure that is poorly controlled with 3 drugs or requiring 4 drugs for control. The diagnosis of resistant hypertension requires exclusion of poor compliance, secondary causes, and white coat effect. A possible cause of resistant hypertension that has been previously investigated in small studies is inflammation. In this issue of Hypertension, Chen et al1 report a previously undefined relationship between some biomarkers of inflammation and apparent treatment-resistant hypertension (ATRH) in patients with chronic kidney disease. The investigators analyzed 1359 subjects with ATRH from the Chronic Renal Insufficiency Cohort and 2008 subjects without ATRH. They found that resistant hypertension was associated with a rather marked increase in the inflammatory markers TNF (tumor necrosis factor)-α and IL (interleukin)-6 (odds ratios, 1.49 and 1.29, respectively) and a reduction in levels of TGF (transforming growth factor)-β1. In contrast, blood levels of hsCRP (high-sensitivity C-reactive protein), fibrinogen, IL-1β, and IL-1RA (IL-1 receptor antagonist) were not associated with resistant hypertension. The authors created an inflammatory score, based on the levels of each of these biomarkers and found that higher scores were associated with resistant hypertension. Moreover, participants were followed for an average of 6.7 years and hazard ratios associated with ATRH were 1.49 for cardiovascular diseases and 1.27 for death after adjustment for confounding variables.Why would the Chen et al1 choose to study the role of inflammatory markers in ATRH? Studies during the past decade, largely in experimental animals, have established a role of the immune system in the development of hypertension and its attendant end-organ damage. It is now clear that cells of both the innate and adaptive immune system accumulate in kidneys and vessels of hypertensive animals and humans. These cells release inflammatory cytokines, including IL-17A, TNF-α, IFN (interferon)-γ, IL-6, and others that promote vascular and renal dysfunction and ultimately tissue damage.2 Of relevance to the Chen et al1 study, Filho et al3 have shown that neutralizing circulating TNF-α reduces blood pressure in spontaneously hypertensive rats. Likewise, Guzik et al4 showed TNF-α blockade lowers blood pressure and reduces vascular superoxide production in Ang II (angiotensin II)–infused mice. Mice lacking IL-6 exhibit reduced hypertension and less reduction of renal blood flow during Ang II infusion.5 Thus, the finding of elevated IL-6 and TNF-α in patients with chronic kidney disease and ATRH are in keeping with prior studies in experimental animals.Prior studies have examined the association of hsCRP, IL-6, and TNF-α with hypertension.6,7 Like Chen et al,1 Bautista et al6 found a significant association between blood pressure and plasma levels of TNF-α and IL-6, but no relationship to hsCRP in 196 otherwise healthy subjects. hsCRP has been also been shown to be predictive of the development of hypertension.8 In smaller cohorts of hypertensive subjects, Yu et al7 showed higher levels of TNF-α and IL-6 in hypertensive patients, whereas studies from our group showed higher TNF-α and hsCRP levels, but no differences in IL-6 levels in hypertensive and resistant hypertensive subjects compared with normotensive.9 The Chen et al1 study adds to these prior reports in several ways. First, it was a study not simply of hypertension, but of resistant hypertension, a special subset that is of particular clinical interest. It is very rare to have such a large population of patients with resistant hypertension. Second, it involved patients with chronic kidney disease, a condition where inflammation is common. Among the subjects studied by Chen et al,1 those with resistant hypertension had higher urinary protein and significantly lower glomerular filtration rate as compared to the patients without resistant hypertension, possibly reflecting more severe kidney disease. Multivariate analysis showed a significant relationship between the inflammatory cytokines and resistant hypertension even after correcting for renal function. Although drugs that modify immune responses would unlikely ever be used in humans with easily controlled hypertension, agents like anti–IL-6 or anti–TNF-α might be employed in a high-risk population such those with resistant hypertension.At least 4 of biomarkers studied by Chen et al,1 IL-6, IL-1β, CRP, and TNF-α are intimately related (Figure). IL-1β can signal IL-6, which in turn signals production of CRP. Moreover, TGF-β and IL-6 act in concert to stimulate T cells to produce IL-17. TNF-α can also stimulate production of CRP. It is therefore somewhat surprising that these 3 biomarkers did not track in parallel in the study of Chen et al1; however, there are other examples where these are not equally elevated or seem to provide different prognostic information. There are several potential reasons for discordance between biomarkers like IL-1β, IL-6, and CRP. One is that cytokines like IL-6, TNF-α, and IL-1β are produced locally and have very powerful effects on adjacent cells. The amount that enters the circulation may or may not reflect these local concentrations and little is known about factors that influence clearance of these from the blood. Thus, IL-1β might be elevated within the interstitium of the vessel or the kidney, but not changed in the circulation. IL-6 can be stimulated by other stimuli, like the Jak/STAT pathway, which in turn promotes further IL-6 production. Another very important issue relates to the assays involved. Biomarkers like IL-6 and TNF-α are usually measured by enzyme-linked immunosorbent assays or cytokine bead arrays, often in individual laboratories. Such assays are notoriously fickle and are not standardized between one laboratory and the next. There is little information as to stability of these cytokines in stored samples or the coefficient of variation of measurements. Normal IL-6 values have been reported to be <0.5, 1.5, and <4 pg/mL in various studies. In normal subjects, circulating levels of IL-1β are often undetectable.9 Thus, the inability to detect a change in one biomarker might reflect inaccuracy of the bioassay or instability of the biomarker in stored samples. Alternate approaches are being used to characterize immune cells in humans, including analyzing the cytokines they produce after being placed in culture, using high-density phenotyping like mass cytometry (CyTOF) and single-cell sequencing. Another issue is that these biomarkers, like the sedimentation rate or leukocyte count, are not specific for any one disease. IL-6 levels are increased in response to exercise and in conditions like cancer, mental illness, and asthma. Thus, an elevation of a biomarker like IL-6 in any one individual could be because of coexisting conditions and must be evaluated within its clinical context. Antihypertensive drugs, similar to those taken by subjects in the study by Chen et al,1 might also decrease certain circulating cytokines.Download figureDownload PowerPointFigure. Factors in the hypertensive milieu stimulate immune and parenchymal cells, including endothelial cells and renal cells to produce inflammatory cytokines. Activated immune cells infiltrate target organs, including the kidney and vasculature, leading to renal and vascular dysfunction. These factors not only worsen blood pressure (BP) elevation but also promote end-organ damage. Chen et al1 devised an inflammatory score that was elevated in subjects with treatment-resistant hypertension and was associated with increased cardiovascular (CV) events. ARHTN indicates apparent resistant hypertension; CKD, chronic kidney disease, hsCRP, high-sensitivity C-reactive protein; IL, interleukin; TGF, transforming growth factor; and TNF, tumor necrosis factor.Beyond the issue mentioned above, the finding that some cytokines, like TNF-α and IL-6, but not others, like IL-1β and TGF-β are elevated in hypertension might seem inconsistent, because most of these cytokines are considered proinflammatory. It is critical to understand that not all inflammation is the same, a fact recognized by rheumatologists for years. An example is IL-17, which has been implicated in the pathophysiology of several autoimmune diseases including psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, asthma, and multiple sclerosis. Although blockade of IL-17 has proven extremely useful in several of these, it is ineffective in Crohn disease.10 Another example is blockade of IL-6, which is highly effective in rheumatoid arthritis but less effective in ankylosing spondylitis.11 Two recent large clinical trials have highlighted this concept for treatment of cardiovascular disease. The CANTOS trial (Canakinumab Antiinflammatory Thrombosis Outcome Study) showed that targeting IL-1β in high-risk patients with previous history of myocardial infarction and high levels of hsCRP reduced cardiovascular events.12 In contrast, low-dose methotrexate failed to reduce cardiovascular events and had no effect on levels of IL-1β, IL-6, and CRP in the CIRT study (Cardiovascular Inflammation Reduction Trial).13 The populations studied in these 2 trials had different levels of hsCRP and therefore their disparate results might be because of varying levels of baseline inflammation; however, another explanation for their discordant results could differences in the actions of these drugs on the underlying pathology of atherosclerotic lesions. Taken together, these studies emphasize the importance of characterizing the immune process in a disease-like hypertension and thereby identifying appropriate therapy. Studies like that of Chen et al1 are informative in the beginning to address this issue.AcknowledgmentsN.R. Barbaro and D.G. Harrison cowrote this editorial.Sources of FundingThis study was supported by National Institutes of Health grants P01HL129941 and R35 HL140016. N.R. Barbaro is a recipient of an American Heart Association Fellowship Award.DisclosuresNone.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.This article was sent to Karen A. Griffin, Guest Editor, for review by expert referees, editorial decision, and final disposition.Correspondence to David G. Harrison, Betty and Jack Bailey Professor of Medicine, Pharmacology and Physiology, Director of Clinical Pharmacology, Room 536, Robinson Research Bldg, Vanderbilt University, Nashville, TN 37232. Email david.g.[email protected]orgReferences1. Chen J, Bundy JD, Hamm LL, et al; for the CRIC Study Investigators. Inflammation and apparent treatment resistant-hypertension in patients with chronic kidney disease: the results from the CRIC study.Hypertension. 2019; 73:785–793. doi: 10.1161/HYPERTENSIONAHA.118.12358LinkGoogle Scholar2. Norlander AE, Madhur MS, Harrison DG. The immunology of hypertension.J Exp Med. 2018; 215:21–33. doi: 10.1084/jem.20171773CrossrefMedlineGoogle Scholar3. Filho AG, Kinote A, Pereira DJ, Rennó A, dos Santos RC, Ferreira-Melo SE, Velloso LA, Bordin S, Anhê GF, Moreno Junior H. Infliximab prevents increased systolic blood pressure and upregulates the AKT/eNOS pathway in the aorta of spontaneously hypertensive rats.Eur J Pharmacol. 2013; 700:201–209. doi: 10.1016/j.ejphar.2012.11.059CrossrefMedlineGoogle Scholar4. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction.J Exp Med. 2007; 204:2449–2460. doi: 10.1084/jem.20070657CrossrefMedlineGoogle Scholar5. Brands MW, Banes-Berceli AK, Inscho EW, Al-Azawi H, Allen AJ, Labazi H. Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation.Hypertension. 2010; 56:879–884. doi: 10.1161/HYPERTENSIONAHA.110.158071LinkGoogle Scholar6. Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension.J Hum Hypertens. 2005; 19:149–154. doi: 10.1038/sj.jhh.1001785CrossrefMedlineGoogle Scholar7. Yu X, Yang Z, Yu M. Correlation of tumor necrosis factor alpha and interleukin 6 with hypertensive renal damage.Ren Fail. 2010; 32:475–479. doi: 10.3109/08860221003664280CrossrefMedlineGoogle Scholar8. Hage FG. C-reactive protein and hypertension.J Hum Hypertens. 2014; 28:410–415. doi: 10.1038/jhh.2013.111CrossrefMedlineGoogle Scholar9. Barbaro NR, Fontana V, Modolo R, De Faria AP, Sabbatini AR, Fonseca FH, Anhê GF, Moreno H. Increased arterial stiffness in resistant hypertension is associated with inflammatory biomarkers.Blood Press. 2015; 24:7–13. doi: 10.3109/08037051.2014.940710CrossrefMedlineGoogle Scholar10. Hueber W, Sands BE, Lewitzky S, et al; Secukinumab in Crohn's Disease Study Group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.Gut. 2012; 61:1693–1700. doi: 10.1136/gutjnl-2011-301668CrossrefMedlineGoogle Scholar11. Puchner A, Blüml S. IL-6 blockade in chronic inflammatory diseases.Wien Med Wochenschr. 2015; 165:14–22. doi: 10.1007/s10354-014-0321-xCrossrefMedlineGoogle Scholar12. Ridker PM, Everett BM, Thuren T, et al; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease.N Engl J Med. 2017; 377:1119–1131. doi: 10.1056/NEJMoa1707914CrossrefMedlineGoogle Scholar13. Ridker PM, Everett BM, Pradhan A, et al; CIRT Investigators. Low-dose methotrexate for the prevention of atherosclerotic events.N Engl J Med. 2019; 380:752–762. doi: 10.1056/NEJMoa1809798CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Souders C, Zubcevic J and Martyniuk C (2021) Tumor Necrosis Factor Alpha and the Gastrointestinal Epithelium: Implications for the Gut-Brain Axis and Hypertension, Cellular and Molecular Neurobiology, 10.1007/s10571-021-01044-z, 42:2, (419-437), Online publication date: 1-Mar-2022. Rodrigues-Diez R, Tejera-Muñoz A, Orejudo M, Marquez-Exposito L, Santos-Sanchez L, Rayego-Mateos S, Cantero-Navarro E, Tejedor-Santamaria L, Marchant V, Ortiz A, Egido J, Mezzano S, Selgas R, Navarro-González J, Valdivielso J, Lavoz C and Ruiz-Ortega M (2021) Interleukin-17A: Potential mediator and therapeutic target in hypertension, Nefrología (English Edition), 10.1016/j.nefroe.2021.06.003, 41:3, (244-257), Online publication date: 1-May-2021. Rodrigues-Diez R, Tejera-Muñoz A, Orejudo M, Marquez-Exposito L, Santos L, Rayego-Mateos S, Cantero-Navarro E, Tejedor-Santamaria L, Marchant V, Ortiz A, Egido J, Mezzano S, Selgas R, Navarro-González J, Valdivielso J, Lavoz C and Ruiz-Ortega M (2021) Interleuquina-17A: posible mediador y diana terapéutica en la hipertensión, Nefrología, 10.1016/j.nefro.2020.11.009, 41:3, (244-257), Online publication date: 1-May-2021. Rai A, Narisawa M, Li P, Piao L, Li Y, Yang G and Cheng X (2020) Adaptive immune disorders in hypertension and heart failure: focusing on T-cell subset activation and clinical implications, Journal of Hypertension, 10.1097/HJH.0000000000002456, 38:10, (1878-1889), Online publication date: 1-Oct-2020. Rodríguez-Iturbe B (2020) The participation of immunity in the pathogenesis of arterial hypertension, Nefrología (English Edition), 10.1016/j.nefroe.2019.04.005, 40:1, (1-3), Online publication date: 1-Jan-2020. Rodríguez-Iturbe B (2020) La participación de la inmunidad en la patogenia de la hipertensión arterial, Nefrología, 10.1016/j.nefro.2019.04.006, 40:1, (1-3), Online publication date: 1-Jan-2020. Pioli M and de Faria A (2019) Pro-inflammatory Cytokines and Resistant Hypertension: Potential for Novel Treatments?, Current Hypertension Reports, 10.1007/s11906-019-1003-2, 21:12, Online publication date: 1-Dec-2019. Sylvester M and Brooks H (2019) Sex-Specific Mechanisms in Inflammation and Hypertension, Current Hypertension Reports, 10.1007/s11906-019-0959-2, 21:7, Online publication date: 1-Jul-2019. Berzinji B and Dizaye K (2022) Investigating the effect of Fenofibrate on biomarkers of vascular inflammation in L-NAME induced hypertensive rats, Pharmacia, 10.3897/pharmacia.69.e81078, 69:2, (459-465) Litvinova M, Khaisheva L and Shlyk S (2020) Resistant hypertension: focus on vascular lesions, South Russian Journal of Therapeutic Practice, 10.21886/2712-8156-2020-1-3-16-26, 1:3, (16-26) Related articlesInflammation and Apparent Treatment-Resistant Hypertension in Patients With Chronic Kidney DiseaseJing Chen, et al. Hypertension. 2019;73:785-793 April 2019Vol 73, Issue 4 Advertisement Article InformationMetrics © 2019 American Heart Association, Inc.https://doi.org/10.1161/HYPERTENSIONAHA.119.12604PMID: 30776975 Originally publishedFebruary 19, 2019 PDF download Advertisement SubjectsBiomarkersHypertensionInflammationTranslational Studies
Referência(s)